

**SUPPLEMENT NO. 9 DATED 18 NOVEMBER 2014 TO  
THE BASE PROSPECTUS DATED 11 MARCH 2014**

**Merrill Lynch B.V.**  
*(a Dutch Private Limited Liability Company)*

**Merrill Lynch International & Co. C.V.**  
*(a Curaçao Limited Partnership)*

**NOTE, WARRANT AND CERTIFICATE PROGRAMME**

Unconditionally and irrevocably guaranteed by

**Bank of America Corporation**  
*(a Delaware (U.S.A.) corporation)*

This supplement (the "**Supplement**") constitutes a supplement to the base prospectus of Merrill Lynch B.V. ("**MLBV**") and Merrill Lynch International & Co. C.V. ("**MLICo.**") dated 11 March 2014 (the "**Original Base Prospectus**"), and, as supplemented on 1 April 2014, 22 April 2014, 9 May 2014, 18 July 2014, 6 August 2014, 2 September 2014, 8 October 2014, and 22 October 2014, the "**Base Prospectus**"), prepared in connection with the Note, Warrant and Certificate Programme (the "**Programme**") of MLBV and MLICo., unconditionally and irrevocably guaranteed in respect of Securities issued by MLBV and MLICo. as to payment and non-cash delivery obligations by Bank of America Corporation ("**BAC**"). The Supplement is a supplement for the purposes of Article 13 of Chapter 1 of Part II of the Luxembourg Law dated 10 July 2005 and amended on 3 July 2012 on prospectuses for securities (the "**Luxembourg Law**"). On 11 March 2014, the Commission de Surveillance du Secteur Financier (the "**CSSF**") approved the Original Base Prospectus for the purposes of Article 7 of the Luxembourg Law. Terms defined in the Base Prospectus have the same meanings when used in this Supplement.

This Supplement is supplemental to, and shall be read in conjunction with, the Base Prospectus. To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in or incorporated by reference into the Base Prospectus, the statements in (a) above will prevail.

Each of MLICo., MLBV and BAC accepts responsibility for the information contained in this Supplement and to the best of the knowledge of MLICo., MLBV and BAC (each having taken all reasonable care to ensure that such is the case), the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Save as disclosed in this Supplement or in the document incorporated by reference in, and forming part of, this Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to the information included in the Base Prospectus since the publication of the Base Prospectus as supplemented from time to time.

Copies of this Supplement and the document incorporated by reference will be available for collection and inspection as set out in the section entitled "*General Information – Documents Available*" in the Original Base Prospectus (at pages 604-605) and on the Luxembourg Stock Exchange's website at [www.bourse.lu](http://www.bourse.lu).

In accordance with Article 13 paragraph 2 of the Luxembourg Law, investors in the European Economic Area who have already agreed to purchase or subscribe for Securities issued under the Programme before this Supplement is published have the right, exercisable within two working days after the publication of this Supplement, to withdraw their acceptances. This right will expire on 20 November 2014. The right to withdraw acceptances does not extend to investors in Securities offered in Switzerland.

## ***I. Incorporation by Reference of BAC 6 November 2014 Form 10-Q***

BAC's quarterly unaudited report on Form 10-Q dated 6 November 2014 in respect of the nine months ended 30 September 2014 which was filed with the U.S. Securities and Exchange Commission (the "SEC") on 6 November 2014 (the "**6 November 2014 Form 10-Q**"), has been filed with the CSSF in its capacity as competent authority under Article 21(1) of the Prospectus Directive. By virtue of this Supplement, the sections of the 6 November 2014 Form 10-Q referred to below are incorporated by reference into, and form part of, the Base Prospectus. The information included in the 6 November 2014 Form 10-Q that is not listed in the column "*Information incorporated by reference*" below, is considered as additional information and is not required by the relevant schedules of the Commission Regulation (EC) No 809/2004.

*Each page reference in the table below refers to the corresponding page in the 6 November 2014 Form 10-Q:*

<b>Information Incorporated by Reference From the 6 November 2014 Form 10-Q</b>	<b>Page Number</b>
Part I	
<i>Item 1. Financial Statements (unaudited)</i>	<i>Pages 142-248</i>
<i>Consolidated Statement of Income</i>	<i>Page 142</i>
<i>Consolidated Statement of Comprehensive Income</i>	<i>Page 143</i>
<i>Consolidated Balance Sheet</i>	<i>Pages 144-145</i>
<i>Consolidated Statement of Changes in Shareholders' Equity</i>	<i>Page 146</i>
<i>Consolidated Statement of Cash Flows</i>	<i>Page 147</i>
<i>Notes to Consolidated Financial Statements</i>	<i>Pages 148-248</i>
<i>1 – Summary of Significant Accounting Principles</i>	<i>Pages 148-149</i>
<i>2 – Derivatives</i>	<i>Pages 150-161</i>
<i>3 – Securities</i>	<i>Pages 162-166</i>
<i>4 – Outstanding Loans and Leases</i>	<i>Pages 167-186</i>
<i>5 – Allowance for Credit Losses</i>	<i>Pages 187-188</i>
<i>6 – Securitizations and Other Variable Interest Entities</i>	<i>Pages 189-197</i>
<i>7 – Representations and Warranties Obligations and Corporate Guarantees</i>	<i>Pages 198-205</i>
<i>8 – Goodwill and Intangible Assets</i>	<i>Pages 206-207</i>
<i>9 – Federal Funds Sold or Purchased, Securities Financing Agreements and Short-term Borrowings</i>	<i>Pages 208-209</i>
<i>10 – Commitments and Contingencies</i>	<i>Pages 210-215</i>
<i>11 – Shareholders' Equity</i>	<i>Pages 215-216</i>
<i>12 – Accumulated Other Comprehensive (Loss)</i>	<i>Pages 217-218</i>
<i>13 – Earning Per Common Share</i>	<i>Page 219</i>
<i>14 – Fair Value Measurements</i>	<i>Pages 220-236</i>
<i>15 – Fair Value Option</i>	<i>Pages 237-239</i>
<i>16 – Fair Value of Financial Instruments</i>	<i>Pages 240-241</i>
<i>17 – Mortgage Servicing Rights</i>	<i>Pages 242-243</i>
<i>18 – Business Segment Information</i>	<i>Pages 244-248</i>
 <i>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</i>	 <i>Page 3</i>
<i>Executive Summary</i>	<i>Pages 4-16</i>
<i>Recent Events</i>	<i>Pages 5-6</i>
<i>Selected Financial Data</i>	<i>Page 7</i>
<i>Financial Highlights</i>	<i>Page 8-10</i>
<i>Balance Sheet Overview</i>	<i>Pages 11-16</i>
<i>Supplemental Financial Data</i>	<i>Pages 17-27</i>

<i>Business Segment Operations</i>	<i>Pages 28-29</i>
<i>Consumer &amp; Business Banking</i>	<i>Pages 30-34</i>
<i>Consumer Real Estate Services</i>	<i>Pages 35-41</i>
<i>Global Wealth &amp; Investment Management</i>	<i>Pages 42-43</i>
<i>Global Banking</i>	<i>Pages 44-47</i>
<i>Global Markets</i>	<i>Pages 48-50</i>
<i>All Other</i>	<i>Pages 51-53</i>
<i>Off-Balance Sheet Arrangements and Contractual Obligations</i>	<i>Pages 54-61</i>
<i>Regulatory Matters</i>	<i>Pages 62-63</i>
<i>Managing Risk</i>	<i>Page 63</i>
<i>Strategic Risk Management</i>	<i>Page 63</i>
<i>Capital Management</i>	<i>Pages 64-74</i>
<i>Liquidity Risk</i>	<i>Pages 74-81</i>
<i>Credit Risk Management</i>	<i>Pages 82-121</i>
<i>Consumer Portfolio Credit Risk Management</i>	<i>Pages 83-102</i>
<i>Commercial Portfolio Credit Risk Management</i>	<i>Pages 103-114</i>
<i>Non-U.S. Portfolio</i>	<i>Pages 114-115</i>
<i>Provision for Credit Losses</i>	<i>Page 116</i>
<i>Allowance for Credit Losses</i>	<i>Pages 117-121</i>
<i>Market Risk Management</i>	<i>Pages 122-132</i>
<i>Trading Risk Management</i>	<i>Pages 122-128</i>
<i>Interest Rate Risk Management for Nontrading Activities</i>	<i>Pages 128-132</i>
<i>Mortgage Banking Risk Management</i>	<i>Page 132</i>
<i>Compliance Risk Management</i>	<i>Page 133</i>
<i>Operational Risk Management</i>	<i>Pages 133-134</i>
<i>Complex Accounting Estimates</i>	<i>Pages 134-137</i>
<i>Glossary</i>	<i>Pages 138-140</i>
<i>Item 3. Quantitative and Qualitative Disclosures about Market Risk</i>	<i>Page 141</i>
<i>Item 4. Controls and Procedures</i>	<i>Page 141</i>
<b>Part II</b>	
<i>Item 1. Legal Proceedings</i>	<i>Page 249</i>
<i>Item 1A. Risk Factors</i>	<i>Page 249</i>
<i>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</i>	<i>Page 249</i>
<i>Item 6. Exhibits</i>	<i>Page 250</i>
<i>Signature</i>	<i>Page 251</i>
<i>Index to Exhibits</i>	<i>Page 252</i>
<i>Exhibit 12</i>	<i>Page 519*</i>

\*This page number is a reference to the PDF page included in the 6 November 2014 Form 10-Q.

II. *Amendments to the Summary of the Original Base Prospectus*

By virtue of this Supplement, the information contained within section B.19 (B.12) "Selected historical key financial information" in the Original Base Prospectus (on pages 18 to 19) shall be deleted and replaced with the following:

**"BAC**

	Nine Months Ended 30 September		Year ended 31 December		
	2014	2013	2013	2012	2011
(Unaudited)					
(Dollars in millions, except number of shares and per share information)					
<b>Income Statement:</b>					
Interest income	\$38,734	\$41,308	\$55,020	\$57,400	\$66,236
Interest expense	8,417	9,829	12,755	16,744	21,620
Net interest income	30,317	31,479	42,265	40,656	44,616
Noninterest income	35,205	35,975	46,677	42,678	48,838
Total revenue, net of interest expense	65,522	67,454	88,942	83,334	93,454
Provision for credit losses	2,056	3,220	3,556	8,169	13,410
Noninterest expense	60,921	51,907	69,214	72,093	80,274
Income before income taxes	2,545	12,327	16,172	3,072	(230)
Income tax expense	762	4,335	4,741	(1,116)	(1,676)
Net income	1,783	7,992	11,431	4,188	1,446
Net income applicable to common shareholders	1,051	6,899	10,082	2,760	85
Average common shares issued and outstanding (in thousands)	10,531,688	10,764,216	10,731,165	10,746,028	10,142,625
Average diluted common shares issued and outstanding (in thousands)	10,587,841	11,523,649	11,491,418	10,840,854	10,254,824
<b>Per common share information:</b>					
Earnings	\$0.10	\$0.64	\$0.94	\$0.26	\$0.01
Diluted earnings	0.10	0.62	0.90	0.25	0.01
Dividends paid	0.07	0.03	0.04	0.04	0.04

	30 September		31 December	
	2014	2013	2013	2012
(Unaudited)				
(Dollars in millions, except percentages)				
<b>Balance Sheet (period-end):</b>				
Total loans and leases	\$891,315	\$934,392	\$928,233	\$907,819
Total assets	2,123,613	2,126,653	2,102,273	2,209,974
Total deposits	1,111,981	1,110,118	1,119,271	1,105,261
Long-term debt	250,115	255,331	249,674	275,585
Total shareholders' equity	238,681	232,282	232,685	236,956
Allowance for loan and lease losses as a percentage of total loans and leases outstanding <sup>1</sup>	1.71 %	2.10%	1.90%	2.69%
Total ending equity to total ending assets	11.24 %	10.92%	11.07%	10.72%

<sup>1</sup> Outstanding loan and lease balances and ratios do not include loans accounted for under the fair value option.

There has been no material adverse change in the prospects of BAC and its subsidiaries on a consolidated basis since 31 December 2013. There has been no significant change in the financial or trading position of BAC and its subsidiaries on a consolidated basis since 30 September 2014."

### III. Amendments to the section entitled Selected Financial Data of Bank of America Corporation

The whole of the section entitled "Selected Financial Data of Bank of America Corporation" up to (but excluding) the heading "Principal Shareholders" (on page 556) of the Original Base Prospectus shall be deleted and replaced with the following:

"The following table contains BAC's selected financial data (1) as of 31 December 2013 and 2012, and for each of the years in the three years ended 31 December 2013, extracted from BAC's audited financial statements and (2) as of and for the nine months ended 30 September 2014 and 2013, extracted from BAC's unaudited financial statements, which were prepared in conformity with accounting principles generally accepted in the United States. BAC's unaudited financial statements include all adjustments, consisting only of normal recurring accruals, that BAC considers necessary for a fair statement of its financial position and its results of operations as of such dates and for such periods. Results for the nine months ended 30 September 2014 are not necessarily indicative of the results that might be expected for any other interim period or for the year as a whole. Certain prior period amounts have been reclassified to conform to current period classifications.

	Nine Months Ended 30 September		Year ended 31 December		
	2014	2013	2013	2012	2011
<b>(Unaudited)</b>					
<b>(Dollars in millions, except number of shares and per share information)</b>					
<b>Income Statement:</b>					
Interest income	\$38,734	\$41,308	\$55,020	\$57,400	\$66,236
Interest expense	8,417	9,829	12,755	16,744	21,620
Net interest income	30,317	31,479	42,265	40,656	44,616
Noninterest income	35,205	35,975	46,677	42,678	48,838
Total revenue, net of interest expense	65,522	67,454	88,942	83,334	93,454
Provision for credit losses	2,056	3,220	3,556	8,169	13,410
Noninterest expense	60,921	51,907	69,214	72,093	80,274
Income before income taxes	2,545	12,327	16,172	3,072	(230)
Income tax expense	762	4,335	4,741	(1,116)	(1,676)
Net income	1,783	7,992	11,431	4,188	1,446
Net income applicable to common shareholders	1,051	6,899	10,082	2,760	85
Average common shares issued and outstanding (in thousands)	10,531,688	10,764,216	10,731,165	10,746,028	10,142,625
Average diluted common shares issued and outstanding (in thousands)	10,587,841	11,523,649	11,491,418	10,840,854	10,254,824
<b>Per common share information:</b>					
Earnings	\$0.10	\$0.64	\$0.94	\$0.26	\$0.01
Diluted earnings	0.10	0.62	0.90	0.25	0.01
Dividends paid	0.07	0.03	0.04	0.04	0.04
<b>30 September</b>					
<b>31 December</b>					
	2014	2013	2013	2012	
<b>(Unaudited)</b>					
<b>(Dollars in millions, except percentages)</b>					
<b>Balance Sheet (period-end):</b>					
Total loans and leases	\$891,315	\$934,392	\$928,233	\$907,819	

Total assets	2,123,613	2,126,653	2,102,273	2,209,974
Total deposits	1,111,981	1,110,118	1,119,271	1,105,261
Long-term debt	250,115	255,331	249,674	275,585
Total shareholders' equity	238,681	232,282	232,685	236,956
Allowance for loan and lease losses as a percentage of total loans and leases outstanding <sup>1</sup>	1.71 %	2.10%	1.90%	2.69%
Total ending equity to total ending assets	11.24 %	10.92%	11.07%	10.72%

<sup>1</sup> Outstanding loan and lease balances and ratios do not include loans accounted for under the fair value option.

## Share Capital

As of 30 September 2014, the issued and outstanding common stock of BAC equalled 10,515,893,904 shares, \$0.01 par value, fully paid, which shares and additional paid in capital equalled approximately \$153.472 billion. As at the date of this Base Prospectus, the authorised common stock of BAC is 12,800,000,000 shares.

As of 30 September 2014, the issued and outstanding preferred stock of BAC equalled 3,591,790 shares, \$0.01 par value, fully paid, with an aggregate liquidation preference of approximately \$17.913 billion. The authorised preferred stock of BAC is 100,000,000 shares."

## IV. Amendments to the section entitled General Information

By virtue of this Supplement, the information contained within the "General Information" section of the Original Base Prospectus, at paragraph (6) (on page 606) entitled "Significant or Material Change", shall be deleted and replaced with the following:

"There has been no significant change in the financial or trading position of MLBV or MLICo. since 30 June 2013. There has been no significant change in the financial or trading position of BAC and its subsidiaries on a consolidated basis since 30 September 2014.

There has been no material adverse change in the prospects of MLBV or MLICo. since 31 December 2012. There has been no material adverse change in the prospects of BAC and its subsidiaries on a consolidated basis since 31 December 2013."